In vivo demonstration of globotriaosylceramide brain accumulation in Fabry Disease using MR Relaxometry
Neuroradiology · 2024
DOI: 10.1007/s00234-024-03380-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroradiology, 2024. Verfasst von Giuseppe Pontillo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini 5, 80131, Naples, Italy. Hauptthemen laut MEDLINE: Fabry Disease, Magnetic Resonance Imaging, Trihexosylceramides. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Napoli Federico II.
Abstract (Originalsprache)
Purpose
How to measure brain globotriaosylceramide (Gb3) accumulation in Fabry Disease (FD) patients in-vivo is still an open challenge. The objective of this study is to provide a quantitative, non-invasive demonstration of this phenomenon using quantitative MRI (qMRI).
Methods
In this retrospective, monocentric cross-sectional study conducted from November 2015 to July 2018, FD patients and healthy controls (HC) underwent an MRI scan with a relaxometry protocol to compute longitudinal relaxation rate (R1) maps to evaluate gray (GM) and white matter (WM) lipid accumulation. In a subgroup of 22 FD patients, clinical (FAbry STabilization indEX -FASTEX- score) and biochemical (residual α-galactosidase activity) variables were correlated with MRI data. Quantitative maps were analyzed at both global (“bulk” analysis) and regional (“voxel-wise” analysis) levels.
Results
Data were obtained from 42 FD patients (mean age = 42.4 ± 12.9, M/F = 16/26) and 49 HC (mean age = 42.3 ± 16.3, M/F = 28/21). Compared to HC, FD patients showed a widespread increase in R1 values encompassing both GM ( p FWE = 0.02) and WM ( p FWE = 0.02) structures. While no correlations were found between increased R1 values and FASTEX score, a significant negative correlation emerged between residual enzymatic activity levels and R1 values in GM ( r = -0.57, p = 0.008) and WM ( r = -0.49, p = 0.03).
Conclusions
We demonstrated the feasibility and clinical relevance of non-invasively assessing cerebral Gb3 accumulation in FD using MRI. R1 mapping might be used as an in-vivo quantitative neuroimaging biomarker in FD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini 5, 80131, Naples, Italy.
- Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy.
- Department of Public Health, University of Naples "Federico II", Naples, Italy.
- Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
- Institute of Nanotechnology, National Research Council, Lecce, Italy.
- Department of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini 5, 80131, Naples, Italy. sirio.cocozza@unina.it.
Förderung
- Università degli Studi di Napoli Federico II
Zitieren
APA
Pontillo, G., Tranfa, M., Scaravilli, A., Monti, S., Capuano, I., Riccio, E., Rizzo, M., Brunetti, A., Palma, G., Pisani, A., & Cocozza, S. (2024). In vivo demonstration of globotriaosylceramide brain accumulation in Fabry Disease using MR Relaxometry. Neuroradiology. https://doi.org/10.1007/s00234-024-03380-5
Vancouver
Pontillo G, Tranfa M, Scaravilli A, Monti S, Capuano I, Riccio E, et al. In vivo demonstration of globotriaosylceramide brain accumulation in Fabry Disease using MR Relaxometry. Neuroradiology. 2024. doi:10.1007/s00234-024-03380-5
BibTeX
@article{Pontillo2024,
author = {Pontillo, Giuseppe and Tranfa, Mario and Scaravilli, Alessandra and Monti, Serena and Capuano, Ivana and Riccio, Eleonora and Rizzo, Manuela and Brunetti, Arturo and Palma, Giuseppe and Pisani, Antonio and Cocozza, Sirio},
title = {In vivo demonstration of globotriaosylceramide brain accumulation in Fabry Disease using MR Relaxometry},
journal = {Neuroradiology},
year = {2024},
doi = {10.1007/s00234-024-03380-5}
}
EUVIMED